Literature DB >> 20692466

Mice deficient in neuropeptide PACAP demonstrate increased sensitivity to in vitro kidney hypoxia.

G Horvath1, B Racz, P Szakaly, P Kiss, E Laszlo, L Hau, A Tamas, Z Helyes, A Lubics, H Hashimoto, A Baba, D Reglodi.   

Abstract

One of the well-known effects of pituitary adenylate cyclase activating polypeptide (PACAP) is its neuroprotective and cytoprotective actions including renoprotective effects. Mice deficient in endogenous PACAP exhibit several behavioral, metabolic, and developmental alterations. Furthermore, PACAP-deficient mice have larger infarct volume in a model of cerebral ischemia, delayed axonal regeneration, and increased cell death in cerebellar oxidative stress. We have previously demonstrated that PACAP-deficient mice have increased susceptibility to in vitro oxidative stress, which can be counteracted by exogenous PACAP treatment. These results demonstrate that endogenous PACAP has a protective role against various stressors. The objective of the present study was to investigate whether endogenous PACAP has a protective effect in the kidney against in vitro hypoxia. Kidney cell cultures were isolated from wild-type and PACAP-deficient mice, and cell viability was assessed after in vitro hypoxia induced using CoCl(2). The sensitivity of cells from PACAP-deficient mice was increased to hypoxia: both after 24 and 48 hours of exposure, cell viability was significantly reduced compared with that in control wild-type mice. These results show that endogenous PACAP protects against noxious stimuli in the kidney and that PACAP may act as a stress sensor in renal cells. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20692466     DOI: 10.1016/j.transproceed.2010.05.015

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  5 in total

1.  PACAP is an endogenous protective factor-insights from PACAP-deficient mice.

Authors:  D Reglodi; P Kiss; K Szabadfi; T Atlasz; R Gabriel; G Horvath; P Szakaly; B Sandor; A Lubics; E Laszlo; J Farkas; A Matkovits; R Brubel; H Hashimoto; A Ferencz; A Vincze; Z Helyes; L Welke; A Lakatos; A Tamas
Journal:  J Mol Neurosci       Date:  2012-04-14       Impact factor: 3.444

Review 2.  Effects of Pituitary Adenylate Cyclase Activating Polypeptide on Cell Death.

Authors:  Gabriella Horvath; Dora Reglodi; Eszter Fabian; Balazs Opper
Journal:  Int J Mol Sci       Date:  2022-04-29       Impact factor: 6.208

Review 3.  Protective effects of PACAP in ischemia.

Authors:  Dora Reglodi; Alexandra Vaczy; Eloísa Rubio-Beltran; Antoinette MaassenVanDenBrink
Journal:  J Headache Pain       Date:  2018-03-02       Impact factor: 7.277

Review 4.  The Neuropeptide Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) is Protective in Inflammation and Oxidative Stress-Induced Damage in the Kidney.

Authors:  Gabriella Horvath; Balazs Opper; Dora Reglodi
Journal:  Int J Mol Sci       Date:  2019-10-07       Impact factor: 5.923

Review 5.  Protective Effects of PACAP in Peripheral Organs.

Authors:  Denes Toth; Edina Szabo; Andrea Tamas; Tamas Juhasz; Gabriella Horvath; Eszter Fabian; Balazs Opper; Dora Szabo; Grazia Maugeri; Agata G D'Amico; Velia D'Agata; Viktoria Vicena; Dora Reglodi
Journal:  Front Endocrinol (Lausanne)       Date:  2020-07-14       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.